



**Eiger BioPharmaceuticals to Host Conference Call for Third Quarter 2022
Financial Results and Business Update on Thursday, November 3**

- Live Conference Call and Webcast at 4:30 PM ET -

Palo Alto, Calif., October 24, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, November 3, 2022 at 4:30 PM ET to discuss its third quarter 2022 financial results and provide a business update.

The live and replayed webcast of the call will be available through the company's website at www.eigerbio.com. To participate in the live call by phone, please register in advance at <https://register.vevent.com/register/B187b8efa326b64c63bd59eabef4f465ab> to receive the dial-in number and unique passcode to access the call. The webcast will be archived and available for replay for at least 90 days after the event.

About Eiger

Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. All five Eiger rare disease programs have been granted FDA breakthrough therapy designation.

For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

SOURCE Eiger BioPharmaceuticals, Inc.

Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhousesa.com

Media:
Sarah Mathieson
SVP, Corporate Affairs
smathieson@eigerbio.com